{
    "nctId": "NCT03272477",
    "briefTitle": "Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients",
    "officialTitle": "A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 257,
    "primaryOutcomeMeasure": "Pathological complete response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, age at diagnosis 18 years and older\n* Histologically confirmed unilateral primary invasive carcinoma of the breast\n* Patients must qualify for neoadjuvant treatment as follows:\n\n  * No clinical evidence for distant metastasis (M0)\n  * Clinical cT1c-T4a-c (participation of patients with tumors \\> cT2 is strongly recommended) and no evidence for distant metastases (M0)\n  * All clinical N (participation of patients with cN+, also in case of cT1c, is strongly recommended)\n  * Known positive HR-status and centrally confirmed HER2+-status by IHC/FISH\n  * Patients need to fulfill adequate blood count and organ function to receive chemotherapy (see exclusion criteria).\n* Tumor block available for central pathology review\n* Performance Status ECOG \u2264 1 or KI \u2265 80%\n* Negative pregnancy test (urine or serum) within 7 days prior to registration in premenopausal patients\n* Patients of childbearing potential must accept to implement a highly effective (less than 1% failure rate according to Pearl index) non-hormonal contraceptive measures during the study treatment and for 6 months following the last dose of study treatment (trastuzumab and pertuzumab) such as:\n\n  * Intrauterine device (IUD)\n  * bilateral tubal occlusion\n  * vasectomised partner\n  * sexual abstinence\n* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements\n* The patient must be accessible for treatment and follow-up\n* LVEF \\> 55%; LVEF within normal limits of each institution measured by echocardiography (within 42 days prior to randomization)\n* Normal ECG (within 42 days prior to randomization)\n\nExclusion Criteria:\n\n* Known hypersensitivity reaction to the compounds or incorporated substances\n* Prior malignancy with a disease-free survival of \\< 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri\n* Non-operable breast cancer including inflammatory breast cancer\n* Previous or concurrent treatment with cytotoxic agents for any reason\n* Concurrent treatment with other experimental drugs and participation in another clinical trial or clinical research project within 30 days prior to study entry is excluded\n* Male breast cancer\n* Concurrent pregnancy\n* Breastfeeding\n* Sequential breast cancer\n* Reasons indicating risk of poor compliance\n* Known polyneuropathy \u2265 grade 2\n* Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including but not confined to:\n\n  * Uncompensated chronic heart failure or systolic dysfunction (LVEF \\< 55%, CHF NYHA classes II-IV),\n  * unstable arrhythmias requiring treatment i.e., atrial tachycardia with a heart rate \u2265 100/min at rest, significant ventricular arrhythmia (ventricular tachycardia) or higher-grade AV-block,\n  * Angina pectoris within the last 6 months requiring anti-anginal medication,\n  * Clinically significant valvular heart disease,\n  * Evidence of myocardial infarction on electrocardiogram (ECG),\n  * Poorly controlled hypertension (e.g., systolic \\> 180 mm Hg or diastolic \\> 100 mm Hg).\n* Inadequate organ function including but not confined to:\n\n  * hepatic impairment (Child Pugh Class C)\n  * pulmonary disease (severe dyspnea at rest requiring oxygen therapy)\n* Abnormal blood values:\n\n  * Thrombocytopenia \\> CTCAE grade 1\n  * Increases in ALT/AST \\> CTCAE grade 1\n  * Hypokalaemia \\> CTCAE grade 1\n  * Neutropenia \\> CTCAE grade 1\n  * Anaemia \\> CTCAE grade 1",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}